A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer

Active, not recruiting

• Conditions: Ovarian Cancer; Biomarker

• Registration Number: NCT06483425
• Lead Sponsor: Tongji Hospital

Brief Summary

This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-01
• Status Verified: 2024-06
• Study First Submitted: 2024-06-24
• Study First Submitted QC: 2024-06-27
• Last Update Submitted: 2024-06-27
• Study First Posted: 2024-07-03
• Last Update Posted: 2024-07-03
• Primary Completion: 2028-12-01
• Study Completion: 2028-12-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 2000

Inclusion Criteria

• Patients diagnosed with ovarian cancer.
• Willingness to undergo biomarker testing.
• Ability to provide informed consent for participation in the study.

Exclusion Criteria

• Inability to comply with study requirements or follow-up visits.
• Previous participation in a conflicting clinical trial.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarker explorarion	5 years	Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.

Trial Locations

Locations (1)

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China